$7.47
0.88% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$7.47
-0.40 5.03% 1M
-1.41 15.84% 6M
-2.60 25.80% YTD
-2.76 26.96% 1Y
-32.95 81.53% 3Y
-4.91 39.65% 5Y
+3.78 102.30% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.07 0.88%
ISIN
US92764N1028
Symbol
VIR
Sector
Industry

Key metrics

Market capitalization $1.03b
Enterprise Value $136.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.74
P/S ratio (TTM) P/S ratio 13.08
P/B ratio (TTM) P/B ratio 0.82
Revenue growth (TTM) Revenue growth -33.82%
Revenue (TTM) Revenue $78.62m
EBIT (operating result TTM) EBIT $-540.94m
Free Cash Flow (TTM) Free Cash Flow $-473.07m
Cash position $1.00b
EPS (TTM) EPS $-3.92
P/E forward negative
P/S forward 14.97
EV/Sales forward 1.99
Short interest 7.26%
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
67%
Hold
33%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
79 79
34% 34%
100%
- Direct Costs 17 17
45% 45%
22%
62 62
30% 30%
78%
- Selling and Administrative Expenses 115 115
19% 19%
147%
- Research and Development Expense 471 471
21% 21%
599%
-525 -525
19% 19%
-667%
- Depreciation and Amortization 16 16
36% 36%
21%
EBIT (Operating Income) EBIT -541 -541
20% 20%
-688%
Net Profit -533 -533
11% 11%
-678%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
Business Wire
11 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors sec...
Positive
Seeking Alpha
15 days ago
VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.
Neutral
Business Wire
16 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and ef...
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 587
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today